Endothelial function and arterial stiffness assessment as early surrogate markers of vascular risk in patients with systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 31, Issue 2, 2013, Pages 0295-0301

  Chin, Calvin Woon Loong ^a   Tan, Ru San ^a,b   Thumboo, Julian ^b,c  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Arterial stiffness; Endothelial dysfunction; Flow mediated dilatation; Sub clinical atherosclerosis.; Systemic lupus erythematosus

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; HYDROXYCHLOROQUINE; OMEGA 3 FATTY ACID; PLACEBO;

ARTERIAL STIFFNESS; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY DILATATION; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CAROTID ARTERY PULSE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMORAL ARTERY; HUMAN; NON INVASIVE MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULSE WAVE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; DISEASE COURSE; EARLY DIAGNOSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK FACTOR; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

DISEASE PROGRESSION; EARLY DIAGNOSIS; ENDOTHELIUM, VASCULAR; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULSE WAVE ANALYSIS; RISK ASSESSMENT; RISK FACTORS; VASCULAR DISEASES; VASCULAR STIFFNESS;

MLCS; MLOWN;

EID: 84875786131     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. AGMON-LEVIN N, MOSCA M, PETRI M, SHOENFELD Y: Systemic lupus erythematosus one disease or many? Autoimmun Rev 2012; 11: 593-5.
2. GOVONI M, BOMBARDIERI S, BORTOLUZZI A et al.: Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 2012; 51: 157-68.
3. MOSCA M, TANI C, ARINGER M et al.: Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011; 10: 383-8.
4. UROWITZ MB, BOOKMAN AA, KOEHLER BE, GORDON DA, SMYTHE HA, OGRYZLO MA: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-5.
5. BERNATSKY S, BOIVIN JF, JOSEPH L et al.: Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7.
6. BJORNADAL I, YIN L, GRANATH F, KLARESKOG L, EKBOM A: Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004; 31: 713-9.
7. CHUNG CP, OESER A, AVALOS I, RAGGI P, STEIN CM: Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15: 562-9.
8. MOSCA M, TANI C, CARLI L, BOMBARDIERI S: Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S126-9.
9. LUPI A, BUFFON A, FINOCCHIARO ML, CONTI E, MASERI A, CREA F: Mechanisms of adenosine- induced epicardial coronary arterial dilatation. Eur Heart J 1997; 18: 614-7.
10. MEREDITH IT, ANDERSON TJ, UEHATA A, YEUNG AC, SELWYN AP, GANZ P: Role of endothelium in ischemic coronary syndromes. Am J Cardiol 1993; 72: 27C-31C.
11. GHIADONI L, MOSCA M, TANI C, VIRDIS A, TADDEI S, BOMBARDIERI S: Clinical and methodological aspects of endothelial function in patients with systemic autoimmune diseases. Clin Exp Rheumatol 2008; 26: 680-7.
12. CELERMAJER DS, SORENSEN KE, GOOCH VM et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
13. DUCHARME A, DUPUIS J, MCNICOLL S, HAREL F, TARDIF JC: Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilatation in normal subjects. Am J Cardiol 1999; 84: 952-4 A8.
14. NIGAM A, MITCHELL GF, LAMBERT J, TARDIF JC: Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease. Am J Cardiol 2003; 92: 395-9.
15. LAKATTA EG: Arterial and cardiac aging: major shareholders in cardio-vascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003; 107: 490-7.
16. LAURENT S, COCKCROFT J, VAN BORTEL L et al.: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-605.
17. EL-MAGADMI M, BODILL H, AHMAD Y et al.: Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404.
18. STALC M, TOMSIC M, JEZOVNIK MK, POREDOS P: Endothelial-dependent and independent dilatation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid syndrome. Clin Exp Rheumatol 2011; 29: 616-23.
19. AHMADI B, BONAKDAR ZS, HASHEMI SM, SADRKABIR SM, KARIMIFAR M: Endothelial dysfunction in Iranian lupus patients. Rheumatol Int 2011; 31: 27-31.
20. GHOSH P, KUMAR A, KUMAR S, AGGARWAL A, SINHA N, MISRA R: Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. Clin Rheumatol 2009; 28: 1259-65.
21. ZHANG CY, LU LJ, LI FH et al.: Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. J Clin Rheumatol 2009; 15: 111-6.
22. VALDIVIELSO P, GÓMEZ-DOBLAS JJ, MACIAS M et al.: Lupus-associated endothelial dysfunction, disease activity and arteriosclerosis. Clin Exp Rheumatol 2008; 26: 827-33.
23. KARADAG O, CALGUNERI M, ATALAR E et al.: Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol 2007; 26: 695-9.
24. PIPER MK, RAZA K, NUTTALL SL et al.: Impaired endothelial function in systemic lupus erythematosus. Lupus 2007; 16: 84-8.
25. KISS E, SOLTESZ P, DER H et al.: Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 2006; 27: 211-7.
26. WRIGHT SA, O'PREY FM, REA DJ et al.: Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2006; 26: 2281-7.
27. JOHNSON SR, HARVEY PJ, FLORAS JS et al.: Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. Lupus 2004; 13: 590-3.
28. LIMA DS, SATO EI, LIMA VC, MIRANDA F JR, HATTA FH: Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 292-7.
29. MAK A, LIU Y, HO RCM: Endothelium-dependent but not endothelium-independent flowmediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: A metaanalysis and metaregression. J Rheumatol 2011; 38: 1296-303.
30. FERREIRA GA, NAVARRO TP, TELLES RW et al.: Atorvastatin therapy improves endothelial- dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007; 46: 1560-5.
31. BUCHER HC, HENGSTLER P, SCHINDLER C, MEIER G: N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002; 112: 298-304.
32. MCVEIGH GE, BRENNAN GM, COHN JN, FINKELSTEIN SM, HAYES RJ, JOHNSTON GD: Fish oil improves arterial compliance in noninsulin- dependent diabetes mellitus. Arteriosclerosis Thromb 1994; 14: 1425-9.
33. MCVEIGH GE, BRENNAN GM, JOHNSTON GD et al.: Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 33-8.
34. GOODFELLOW J, BELLAMY MF, RAMSEY MW, JONES CJ, LEWIS MJ: Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000; 35: 265-70.
35. OKUMURA T, FUJIOKA Y, MORIMOTO S et al.: Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability. Am J Med Sci 2002; 324: 247-53.
36. MORGAN DR, DIXON LJ, HANRATTY CG et al.: Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure. Am J Cardiol 2006; 97: 547-51.
37. WRIGHT SA, O'PREY FM, MCHENRY MT et al.: A randomized interventional trial of omega- 3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 841-8.
38. RUIZ-IRASTORZA G, RAMOS-CASALS M, BRITO-ZERON P, KHAMASHTA MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systemic review. Ann Rheum Dis 2010; 69: 20-8.
39. ROMERO-DIAZ J, VARGAS-VORACKOVA F, KIMURA-HAYAMA E et al.: Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford) 2012; 51: 110-9.
40. SACHET JC, BORBA EF, BONFA E et al.: Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus erythematous. Lupus 2007; 16: 273-8.
41. JOHANSSON E, FORSBERG K, JOHNSSON H: Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981; 10: 89-96.
42. PETRI M, YOO SS: Predictors of glucose intolerance in systemic lupus erythematosus. Arthritis Rheum 1994; 37: S323.
43. TAM LS, LI EK, LEUNG VY et al.: Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study. J Rheumatol 2005; 32: 275-82.
44. PIPER MK, RAZA K, NUTTALL SL et al.: Impaired endothelial function in systemic lupus erythematosus. Lupus 2007; 16: 84-8.
45. CYPIENE A, KOVAITE M, VENALIS A et al.: Arterial wall dysfunction in systemic lupus erythematosus. Lupus 2009; 18: 522-9.
46. CACCIAPAGLIA F, ZARDI EM, COPPOLINO G et al.: Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. Lupus 2009; 18: 249-56.
47. SHANG Q, TAM LS, LI EK, YIP GW, YU CM: Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus 2008;17: 1096-102.
48. ROMAN MJ, DEVEREUZ RB, SCHWARZ JE et al.: Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46: 194-9.
49. BJARNEGRAD N, BENTSSON C, BRODSZKI J, STURFELT G, NIVED O, LANNE T: Increased aortic pulse wave velocity in middle aged women with systemic lupus erythematosus. Lupus 2006; 15: 644-50.
50. YILDIZ M, YILDIZ BS, SOY M, TUTKAN H: Impairment of arterial distensibility in premenopausal women with systemic lupus erythematosus. Kardiol Pol 2008; 66: 1194-9.
51. CYPIENE A, DADONIENE J, RUGIENE R et al.: The influence of mean blood pressure on arterial stiffening and endothelial dysfunction in women with rheumatoid arthritis and systemic lupus erythematosus. Medicina (Kaunas) 2010; 46: 522-30.
52. TSO TK, HUANG WN, HUANG HY, CHANG CK: Association of brachial-ankle pulse wave velocity with cardiovascular risk factors in systemic lupus erythematosus. Lupus 2005; 14: 878-83.
53. SABIO JM, VARGAS-HITOS J, ZAMORAPASADAS M et al.: Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 2009; 36: 2204-11.
54. TSO TK, HUANG HY, CHANG CK, HUANG WN: A positive correlation between homocysteine and brachial-ankle pulse wave velocity in patients with systemic lupus erythematosus. Clin Rheumatol 2006; 25: 285-90.
55. SELZER F, SUTTON-TYRREL K, FITZGERALD S, TRACY R, KULLER L, MANZI S: Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001; 37: 1075-82.
56. KUDARAVALLI J: Improvement in endothelial dysfunction in patients with systemic lupus erythematosus with N-acetylcysteine and atorvastatin. Indian J Pharmacol 2011; 43: 311-5.
57. TEPEI M, VAN DER GIET M, STATZ M, JANKOWSKI J, ZIDEK W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-5.
58. ANDREWS NP, PRASAD A, QUYYUMI AA: N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 2001; 37: 117-23.
59. STAMPFER MJ, RIDKER PM, DZAU VJ: Risk factor criteria. Circulation 2004; 109 (Suppl. 1): IV3-5.
60. COHN JN: Introduction to surrogate markers. Circulation 2004; 109: IV 20-1.
61. KLUFT C: Principles of use of surrogate markers and endpoints. Maturitas 2004; 47: 293-8.